Curis Lifesciences Ltd

Curis Lifesciences Annual General Meeting

Curis Lifesciences filed its 10th AGM notice and FY 2025-26 Annual Report. The meeting is scheduled for September 29, 2026.

Curis Lifesciences Board Meeting Outcome

Curis Lifesciences Limited approved the Director's Report, related party transactions, and scheduled its 10th Annual General Meeting for September 29, 2026. Board outcomes were finalized.

Curis Lifesciences Management Change

Curis Lifesciences Limited announced the resignation of Mr. Nikhil Purohit as Company Secretary and Compliance Officer, effective September 3, 2026.

Curis Lifesciences Other Announcement

Curis Lifesciences Limited submitted the RTA confirmation certificate for the quarter ended June 30, 2026, as required under SEBI Regulation 74(5).

Curis Lifesciences Merger & Restructuring Worth ₹0.05 Cr

Curis Lifesciences Limited has acquired a 49.95% stake in CUROSUN PHARMACEUTICAL NIG LTD, Nigeria, for Rs. 5 Lakhs to expand its pharmaceutical market presence.

Value

₹0.05 Cr

Curis Lifesciences Legal & Regulatory

Curis Lifesciences paid a Rs. 5,900 fine to NSE for delayed RPT disclosure compliance. The Board attributed the delay to technical portal errors.

Curis Lifesciences Management Change

Curis Lifesciences appointed Mr. Devabhai Hamirbhai Jadeja as an Independent Director for five years. He brings extensive experience in financial management and accounting to the board.

Execution

5 years

Curis Lifesciences Results Correction

Curis Lifesciences Limited submitted clarifications and corrected financial results for FY2026 following NSE queries. The update rectifies XBRL discrepancies and integrates issue proceed utilization disclosures.

Curis Lifesciences Management Change

Curis Lifesciences announced the resignation of Independent Director Mr. Chand Rameshbhai Kanabar effective July 3, 2026. His departure is due to pre-occupancy and professional commitments.

Curis Lifesciences Legal & Regulatory

Curis Lifesciences received a fine of ₹0.0059 Crore from NSE. This penalty was imposed for delayed compliance with SEBI Listing Regulations.

Value

₹0.01 Cr

Curis Lifesciences Fund Raise of ₹27.52 Cr

Curis Lifesciences reported its IPO fund utilization for FY2025-26, confirming ₹27.52 Crore was raised. The company reported no deviations in the deployment of these proceeds.

Value

₹27.52 Cr

Curis Lifesciences H2 FY26 Results: Net Profit ₹2.7 Cr, Down 32.5% YoY

Curis Lifesciences Ltd reported revenue from operations of ₹32.7 Cr (-4.9% YoY) and net profit of ₹2.7 Cr (-32.5% YoY) for H2 FY26.

Key figure

Net profit ₹2.7 Cr · -32.5% YoY

Curis Lifesciences Financial Results

Curis Lifesciences Limited approved its audited standalone financial results for the year ended March 31, 2026. The results provide essential year-end performance data for investors.

Curis Lifesciences Other Announcement

Curis Lifesciences Limited filed its annual SDD compliance certificate for FY2026. The company confirmed full adherence to SEBI Insider Trading regulations regarding digital databases.

Curis Lifesciences Board Meeting Date

Curis Lifesciences Limited scheduled a board meeting on May 30, 2026, to approve audited annual results. The company's trading window remains closed for designated persons.

Curis Lifesciences Other Announcement

Curis Lifesciences Limited confirmed its non-applicability as a Large Corporate for FY 2026-27. This regulatory filing clarifies the company is exempt from SEBI debt-raising framework requirements.

Curis Lifesciences Other Announcement

Curis Lifesciences Limited confirmed its non-applicability as a Large Corporate for FY 2026-27. This regulatory filing streamlines compliance requirements for future debt issuances.

Curis Lifesciences Other Announcement

Curis Lifesciences Limited informed the exchange regarding the non-applicability of Corporate Governance and Annual Secretarial Compliance Report requirements for the period ended March 31, 2026. As an NSE SME listed company, it is exempt under Regulation 15(2) of SEBI LODR Regulations, 2015.